@article{duracinsky:inserm-05562555,
  TITLE = {{Patient-reported outcomes among people living with HIV switching to dual therapy with dolutegravir/lamivudine: results from the PROBI study}},
  AUTHOR = {Duracinsky, Martin and Alain, Tristan and Zucman, David and Rousset Torrente, Olivia and Brown Hajdukova, Eva and Hocqueloux, Laurent and Allavena, Clotilde and Marcellin, Fabienne and Chassany, Olivier},
  URL = {https://inserm.hal.science/inserm-05562555},
  JOURNAL = {{Therapeutic Advances in Infectious Disease}},
  PUBLISHER = {{SAGE}},
  VOLUME = {12},
  PAGES = {20499361251321728},
  YEAR = {2025},
  MONTH = Oct,
  DOI = {10.1177/20499361251321728},
  KEYWORDS = {dual therapy ; health-related quality of life (HRQL) ; human immunodeficiency virus (HIV) ; perceived toxicity ; treatment acceptability},
  PDF = {https://inserm.hal.science/inserm-05562555v1/file/duracinsky-et-al-2025-patient-reported-outcomes-among-people-living-with-hiv-switching-to-dual-therapy-with.pdf},
  HAL_ID = {inserm-05562555},
  HAL_VERSION = {v1},
}